Skip to main content
. 2022 Aug;15(8):E53–E60.

FIGURE 2.

FIGURE 2.

RSC protects against telomere shortening in fibroblasts. Human primary adult fibroblasts were treated with the RSC formulation at 500, 125, and 31.25μg/mL for four weeks. The TAT assay was conducted to determine the telomere lengths. Then, the telomere shortening rate was determined by the following formula: median telomere length (initial-final)/population doubling. The values were compared, and the data represent the mean±SD. * p<0.05